Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database resources and/or bioinformatics tools that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the tools and/or resource, user training and services, provision of community-generated data storage and archiving, and wide dissemination of the tools and/or resource.

This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators.

This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug abuse research on HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug abuse and HIV/AIDS that can be carried out in a short period of time with limited resources. Applications under this FOA are welcomed from all areas of HIV/AIDS research that NIDA supports.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, and K23 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease and small vessel disease in the brain, the relationships between them, and how they may contribute to cognitive impairment and dementia.

This Funding Opportunity Announcement (FOA) seeks innovative research proposals that use animal models to investigate the potential role of the microbiome in mediating the latent effects of early life exposure.

This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Support to patients with primary sclerosing cholangitis, an autoimmune disease that causes the bile ducts inside and outside the liver to become scarred, narrowed, and eventually blocked, as well as their families and caregivers, and to raise funds for research on the causes, treatments, and a cure for PSC. To that end, the foundation offers grants of up to $60,000 over two years tor research projects that address an important and novel, basic, or clinical research question related to PSC and closely allied diseases (such as inflammatory bowel diseases, ulcerative colitis, or Crohn's disease).

AIDS United, in collaboration with the Health Resources and Services Administration's HIV/AIDS Bureau and The Fenway Institute, is offering funding through the Using Evidence-Informed Interventions to Improve Health Outcomes among People Living with HIV initiative. The goal of this initiative is to support the implementation of evidence-informed interventions to reduce HIV-related health disparities and improve health outcomes, including increasing retention in care, improving treatment adherence, and improving viral suppression for people living with HIV. Up to 24 intervention sites will receive $170,000 per year to support the development and implementation of interventions. Ryan White HIV/AIDS Program recipients or subrecipients that operate within the United States or its territories are eligible to apply. Proposals must be submitted by January 22, 2018. Visit the AIDS United website to download the RFP.